Phase II Trial of Hypofractionated Radiotherapy and Immunochemotherapy in Primary Refractory Diffuse Large B‐Cell Lymphoma: Preliminary Results and Insights from Digital Spatial Profiling

Phase II Trial of Hypofractionated Radiotherapy and Immunochemotherapy in Primary Refractory Diffuse Large B‐Cell Lymphoma: Preliminary Results and Insights from Digital Spatial Profiling

ABSTRACT This open‐label, single‐arm phase II study assessed the safety and efficacy of sequential hypofractionated radiotherapy (RT) followed by zimberelimab and R‐GemOx (rituximab, gemcitabine, oxaliplatin) in patients with primary refractory diffuse large B‐cell lymphoma (DLBCL). Fourteen patient...

Full description

Saved in:
Bibliographic Details
Main Authors: Yong Yang, Jing Yu, Xiao‐Mei Hu, Si‐Lin Chen, Rui‐Zhi Zhao, Cheng Huang, Jiang‐Rui Guo, Tian‐Lan Tang, Cheng Chen, Yu‐Ping Lin, Ying Wang, Tian‐Xiu Liu, Hao Zheng, Si‐Qin Liao, Jin‐Hua Chen, Hai‐Ying Fu, Ting‐Bo Liu
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:MedComm
Subjects:
diffuse large B‐cell lymphoma
immune system
primary refractory
radiotherapy
zimberelimab
Online Access:https://doi.org/10.1002/mco2.70225
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/mco2.70225

Similar Items